Table 2.
Treatment characteristics before and after propensity score matching
| Before PS-matching | After PS-matching | |||||
|---|---|---|---|---|---|---|
| Ticagrelor (n = 7007) |
Clopidogrel (n = 112940) |
SMD |
Ticagrelor (n = 7007) |
Clopidogrel (n = 14014) |
SMD |
|
| Days treated, median (IQR) | 287 (186, 400) | 392 (231, 783) | 0.491 | 287 (186, 400) | 284 (186, 436) | 0.043 |
| 90–180 days, n (%) | 1649 (23.5) | 19340 (17.1) | 1649 (23.5) | 3220 (23.0) | ||
| 181–365 days, n (%) | 3273 (46.7) | 33575 (29.7) | 3273 (46.7) | 6344 (45.3) | ||
| > 365 days, n (%) | 2085 (29.8) | 60025 (53.1) | 2085 (29.8) | 4450 (31.8) | ||
| Year treatment started, n (%) | 0.842 | 0.580 | ||||
| 2011 | 11 (0.2) | 14718 (13.0) | 11 (0.2) | 1340 (9.6) | ||
| 2012 | 255 (3.6) | 15776 (14.0) | 255 (3.6) | 1492 (10.6) | ||
| 2013 | 726 (10.4) | 17130 (15.2) | 726 (10.4) | 1715 (12.2) | ||
| 2014 | 809 (11.5) | 15564 (13.8) | 809 (11.5) | 1642 (11.7) | ||
| 2015 | 1144 (16.3) | 16806 (14.9) | 1144 (16.3) | 1935 (13.8) | ||
| 2016 | 1701 (24.3) | 17383 (15.4) | 1701 (24.3) | 2601 (18.6) | ||
| 2017 | 2361 (33.7) | 15563 (13.8) | 2361 (33.7) | 3289 (23.5) | ||
| Days enrolled after 90 days of treatment, median (IQR) | 433 (243, 788) | 733 (363, 1294) | 0.600 | 433 (243, 788) | 408 (259, 746) | 0.019 |
PS = propensity score; SMD = standardized mean difference; IQR = interquartile range; OA = osteoarthritis.